These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 20485322)

  • 21. Recent legal developments affecting medical device manufacturers.
    Lough MH
    Healthspan; 1993 Sep; 10(8):21-3. PubMed ID: 10129148
    [No Abstract]   [Full Text] [Related]  

  • 22. The Medical Device Safety Act of 2009.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2009 Apr; 360(15):1550-1. PubMed ID: 19297562
    [No Abstract]   [Full Text] [Related]  

  • 23. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Life after Riegel: a fresh look at medical device preemption one year after Riegel v. Medtronic, Inc.
    Wartman GJ
    Food Drug Law J; 2009; 64(2):291-311. PubMed ID: 19999286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Premarket approval and federal preemption of product liability claims in the wake of Medtronic, Inc. v. Lohr.
    Jarcho DG
    Food Drug Law J; 1996; 51(4):613-8. PubMed ID: 11797730
    [No Abstract]   [Full Text] [Related]  

  • 27. Medical devices; current good manufacturing practice (CGMP) final fule; quality system regulation--FDA. Final rule.
    Fed Regist; 1996 Oct; 61(195):52602-62. PubMed ID: 10168287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drafting warnings for medical products: practical considerations for minimizing litigation.
    Dunne KJ; Patterson KD; Baroumand CR
    Healthspan; 1993 Sep; 10(8):11-20. PubMed ID: 10129147
    [No Abstract]   [Full Text] [Related]  

  • 29. Preemption and malpractice liability.
    Hauser RG
    N Engl J Med; 2009 May; 360(21):2257-8; author reply 2258. PubMed ID: 19458378
    [No Abstract]   [Full Text] [Related]  

  • 30. The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
    Mottes LM
    Seton Hall Law Rev; 2011; 41(2):723-63. PubMed ID: 21739761
    [No Abstract]   [Full Text] [Related]  

  • 31. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R; Yolkut D; Connolly DR
    Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pivotal medical-device case.
    Picca SM
    N Engl J Med; 2008 Apr; 358(16):1758. PubMed ID: 18426011
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 34. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

  • 35. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM; Curfman G
    JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
    [No Abstract]   [Full Text] [Related]  

  • 36. Post-decision diagnosis: medical device preemption alive and mostly well after Medtronic, Inc. v. Lohr.
    Sayler SW; Thomas SM
    Ann Health Law; 1997; 6():185-208. PubMed ID: 10184786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical devices; 30-day notices and 135-day PMA supplement review--FDA. Direct final rule; withdrawal.
    Fed Regist; 1998 Aug; 63(154):42699. PubMed ID: 10182563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Who should protect the public? The Supreme Court and medical device regulation.
    Korobkin R
    N Engl J Med; 2007 Oct; 357(17):1680-1. PubMed ID: 17960010
    [No Abstract]   [Full Text] [Related]  

  • 40. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.